Zealand Pharma A/S (CPH: ZEAL)
Denmark
· Delayed Price · Currency is DKK 728.00
-28.50 (-3.77%)
Dec 20, 2024, 4:59 PM CET
Zealand Pharma Income Statement
Financials in millions DKK. Fiscal year is January - December.
Millions DKK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 76.87 | 342.79 | 103.99 | 108.55 | 192 | 41.33 | Upgrade
|
| Revenue Growth (YoY) | -77.62% | 229.65% | -4.20% | -43.47% | 364.52% | 8.84% | Upgrade
|
| Cost of Revenue | 704.13 | 688.1 | 614.04 | 10.97 | - | 0.42 | Upgrade
|
| Gross Profit | -627.26 | -345.31 | -510.06 | 97.58 | 192 | 40.92 | Upgrade
|
| Selling, General & Admin | 313.73 | 215.93 | 269.51 | 298.21 | 222.39 | 67.88 | Upgrade
|
| Research & Development | 171.23 | - | - | 581.51 | 595.85 | 561.42 | Upgrade
|
| Other Operating Expenses | 3.19 | - | 48.27 | - | - | -0.44 | Upgrade
|
| Operating Expenses | 488.15 | 215.93 | 306.54 | 879.72 | 818.24 | 628.86 | Upgrade
|
| Operating Income | -1,115 | -561.24 | -816.6 | -782.14 | -626.24 | -587.94 | Upgrade
|
| Interest Expense | -28.91 | -25.83 | -57.79 | -4.09 | -49.31 | -3.21 | Upgrade
|
| Interest & Investment Income | 123.91 | 45.32 | 6.54 | 0.04 | 2.02 | 6.29 | Upgrade
|
| Currency Exchange Gain (Loss) | -34.91 | -9.71 | 25.6 | 36.52 | - | 5.52 | Upgrade
|
| Other Non Operating Income (Expenses) | -33.24 | -1.99 | 11.01 | -3.47 | - | -0.19 | Upgrade
|
| EBT Excluding Unusual Items | -1,089 | -553.44 | -831.24 | -753.14 | -673.53 | -579.52 | Upgrade
|
| Merger & Restructuring Charges | - | - | -19.1 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | 42.4 | -8.84 | 2.34 | -3.57 | - | 2.85 | Upgrade
|
| Asset Writedown | -11 | -11 | -1.46 | -2.17 | - | - | Upgrade
|
| Other Unusual Items | - | -135.59 | -122.58 | - | - | - | Upgrade
|
| Pretax Income | -1,057 | -708.87 | -972.04 | -758.89 | -673.53 | -576.68 | Upgrade
|
| Income Tax Expense | -4.61 | -5.13 | -6.43 | -3.95 | -4.81 | -5.14 | Upgrade
|
| Earnings From Continuing Operations | -1,053 | -703.74 | -965.61 | -754.94 | -668.71 | -571.54 | Upgrade
|
| Earnings From Discontinued Operations | - | - | -236.53 | -263.21 | -178.02 | - | Upgrade
|
| Net Income | -1,053 | -703.74 | -1,202 | -1,018 | -846.73 | -571.54 | Upgrade
|
| Net Income to Common | -1,053 | -703.74 | -1,202 | -1,018 | -846.73 | -571.54 | Upgrade
|
| Shares Outstanding (Basic) | 63 | 57 | 46 | 43 | 38 | 34 | Upgrade
|
| Shares Outstanding (Diluted) | 63 | 57 | 46 | 43 | 38 | 34 | Upgrade
|
| Shares Change (YoY) | 15.69% | 22.49% | 7.77% | 11.73% | 13.51% | 10.12% | Upgrade
|
| EPS (Basic) | -16.62 | -12.44 | -26.02 | -23.75 | -22.07 | -16.91 | Upgrade
|
| EPS (Diluted) | -16.62 | -12.44 | -26.02 | -23.75 | -22.07 | -16.91 | Upgrade
|
| Free Cash Flow | -706.42 | -436.91 | -954.02 | -1,234 | -713.76 | -430.49 | Upgrade
|
| Free Cash Flow Per Share | -11.15 | -7.72 | -20.65 | -28.79 | -18.60 | -12.74 | Upgrade
|
| Gross Margin | - | -100.74% | - | 89.89% | 100.00% | 99.00% | Upgrade
|
| Operating Margin | -1451.03% | -163.73% | -785.30% | -720.56% | -326.16% | -1422.45% | Upgrade
|
| Profit Margin | -1369.25% | -205.30% | -1156.05% | -937.99% | -441.00% | -1382.77% | Upgrade
|
| Free Cash Flow Margin | -918.98% | -127.46% | -917.45% | -1136.94% | -371.75% | -1041.52% | Upgrade
|
| EBITDA | -1,106 | -554.72 | -729.52 | -768.57 | -583.54 | -574.26 | Upgrade
|
| EBITDA Margin | - | -161.83% | - | - | - | - | Upgrade
|
| D&A For EBITDA | 9.5 | 6.51 | 87.08 | 13.57 | 42.69 | 13.68 | Upgrade
|
| EBIT | -1,115 | -561.24 | -816.6 | -782.14 | -626.24 | -587.94 | Upgrade
|
| EBIT Margin | - | -163.73% | - | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.